Search / Trial NCT06611137

SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Launched by SUN YAT-SEN UNIVERSITY · Sep 23, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Sbrt Immunotherapy Larynx Preservation Laryngeal Cancer Hypopharynx Cancer

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th
  • * age 18-70
  • * PS score 0-1
  • * normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
  • Exclusion Criteria:
  • * Patients with a combination of other malignant tumours
  • * Individuals with contraindications to immunotherapy

About Sun Yat Sen University

Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.

Locations

Guangzhou, Guangdong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0